%0 Journal Article %A Taejeong Bae %A Liana Fasching %A Yifan Wang %A Joo Heon Shin %A Milovan Suvakov %A Yeongjun Jang %A Scott Norton %A Caroline Dias %A Jessica Mariani %A Alexandre Jourdon %A Feinan Wu %A Arijit Panda %A Rosalinda C. Roberts %A Anita Huttner %A Joel E. Kleinman %A Thomas M. Hyde %A Richard E. Straub %A Christopher A. Walsh %A Brain Somatic Mosaicism Network %A Alexander Urban %A James F. Leckman %A Daniel R. Weinberger %A Flora M. Vaccarino %A Alexej Abyzov %T Somatic mutations reveal hypermutable brains and are associated with neuropsychiatric disorders %D 2022 %R 10.1101/2022.02.09.22269114 %J medRxiv %P 2022.02.09.22269114 %X Somatic mutations have causative roles in many diseases and contribute to neuropsychiatric disorders. Here, we analyzed 131 human brains (44 neurotypical, 19 with Tourette syndrome, 9 with schizophrenia, and 59 with autism) for somatic single nucleotide and structural mutations after whole genome sequencing to a depth of over 200X. Typically, brains had 20 to 60 detectable single nucleotide mutations that likely arose in early development; however, about 5% of brains harbored hundreds and up to 2000 somatic mutations. Hypermutability was associated with age and putative damaging mutations in genes previously implicated in cancer and likely reflects in vivo clonal expansions. Somatic duplications of likely early developmental origin were present in 1 out of 20 normal and diseased brains, reflecting background mutagenesis. Brains of individuals with autism were enriched in somatic deletions and in point mutations that create putative transcription factor binding motifs in enhancers that are active in the developing brain. The most affected motifs corresponded to MEIS transcription factors, suggesting a potential link between their involvement in gene regulation and autism.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The analyzed samples and generated data were de-identified and derived from an individual postmortem. Brains with Tourette Syndrome sequenced by Yale University were obtained from the Harvard Brain and Tissue Resource Center (HBTRC). Normal brains sequenced by Yale University were obtained from NIH NeuroBioBank. The work with those brains was handled in multiple institutes under multiple IRBs: University of Miami Brain Endowment Bank IRB Protocol Number: 19920358 (CR0001775) *IRB: University of Miami Institutional Review Board *Title: Brain Endowment Bank University of Maryland Brain and Tissue Bank IRB Protocol Number: HM-HP-00042077 *IRB: The University of Maryland Institutional Review Board *Title: University of Maryland Brain and Tissue Bank IRB Protocol Number: 5-58 *IRB: The Maryland Department of Health and Mental Hygiene IRB *Title: University of Maryland Brain and Tissue Bank Harvard Brain Tissue Resource Center IRB Protocol Number: 2015P002028 *IRB: Partners Human Research Committee *Title: Brain Tissue Repository for Research on Neurological and Psychiatric Disorders The Human Brain and Spinal Fluid Resource Center (managed by Sepulveda Research Corporation) IRB Protocol Number: PCC#: 2015-060672, VA Project #: 0002 *IRB: Department of Veterans Affairs - Los Angeles *Title: NIH Brain and Tissue Repository - California Mt. Sinai Brain Bank IRB Protocol Number: HAR-13-059 *IRB: Bronx VA Medical Center Institutional Review Board *Title: The NIMH, NICHD, NINDS Brain and Tissue Repository Brain Tissue Donation Program at the University of Pittsburgh IRB Protocol Number: REN14120157/IRB 981146 *IRB: University of Pittsburgh Institutional Review Board *Title: University of Pittsburgh NIMH, NICHD, NINDS Brain and Tissue Repository For normal brains from Yale University autopsy authorization, consent to utilize tissues for research and consent to publish was provided by the patient next-of-kin according to Connecticut state law and approved protocols of the Yale University BioBank. The research study was approved by the Yale Alzheimer Disease Research Center (ADRC) and was reviewed and deemed exempt by the Yale University Institutional Review Board. The BioBank protocols are in accordance with the ethical standards of Yale University. Handling of brains originating from and sequenced by the Lieber Institute was conducted under the approved WCG IRB protocol 20111080 titled Collection of Postmortem Human Brain, Blood and Scalp Samples for Neuropsychiatric Research. Data for brains sequenced by Harvard University were publicly available from NIMH Data Archive. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available in NIMH Data Archive. https://nda.nih.gov/study.html?id=814 %U https://www.medrxiv.org/content/medrxiv/early/2022/02/10/2022.02.09.22269114.full.pdf